health π¬ GLP-1 drugs might fight infections, not just sugar
Recent research indicates that GLP-1 receptor agonists could offer benefits beyond metabolic health by lowering infection risks. An international study involving over 7 million people found these drugs reduced tuberculosis risk in type 2 diabetes patients. These findings suggest GLP-1 agonists might provide extra advantages in infection prevention. A separate US study of 50,000+ adults also linked tirzepatide to lower infection-related mortality. More research is needed to confirm if these medications directly reduce infection susceptibility. π¬